These drugs have generally failed in clinical trials, either causing a marked increase in deaths (torcetrapib), or having no meaningful clinical improvement despite HDL increases (dalcetrapib, evacetrapib). Failed: * Torcetrapib, failed in 2006 due to excess deaths in Phase III clinical trials. * Dalcetrapib, development halted in May 2012 when Phase III trials failed to show clinically meaningful efficacy. * Evacetrapib, development discontinued in 2015 due to insufficient efficacy. * Obicetrapib (TA-8995, AMG-899), Phase II results reported in 2015, discontinued in 2017 Succeeded: * Anacetrapib. In 2017, the REVEAL trial based on more than 30,000 participants showed a modest benefit of the addition of anacetrapib to statin therapy. Despite the successful trial, Merck halted the development of the drug.
CETP inhibitor
Exopeptidase inhibitor
Xanthine oxidase inhibitor
Topoisomerase inhibitor
Protease inhibitor 
Endopeptidase inhibitor
Protein kinase inhibitor
Lipase inhibitors